CYCN

Insider Trades

Name	Value	Action	Price	Current Price
Slate Path Capital LP10 Percent Owner $555k357.9k shares SellNov 21, 2024 $1.55 --

News

prnewswire.comAre UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?prnewswire.comApr 9

prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)prnewswire.comApr 2

businesswire.comCYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.comApr 2

prnewswire.comShareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholdersprnewswire.comApr 1

benzinga.comCyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financingbenzinga.comApr 1

Trade CYCN

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.

CEO: Regina Graul
IPO Date: Mar 18, 2019

Market Data

Open: $3.22
High: $3.30
Low: $3.20
Volume: 36.1K
Avg Volume: 4.6M
52W High: $8.48
52W Low: $1.03

Valuation

Market Cap: $14M
Enterprise Value: $11M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.3M
Revenue: $2.1M
Net Income: $-3.5M
Cash: $3.2M
Debt: $0

Events

EarningsAug 4

EPS est. -7.1